background: Characterization of the normal degree of physiological variation in the metabolomic profiles of healthy humans is a necessary step in the development of metabolomics as both a clinical research and diagnostic tool. This study investigated the effects of the menstrual cycle on 1 H nuclear magnetic resonance (NMR) derived metabolomic profiles of urine and plasma from healthy women.
Introduction
The metabolomic profile of a biofluid can be altered by nutritional state, disease processes or the presence of toxic substances and thus provides an important tool for the study of many physiological processes. However, in addition to perturbation due to disease, the metabolomic profile of urine and plasma has also been shown to vary due to many intrinsic physiological factors such as age, gender, hormonal status and diurnal variation (Kochhar et al., 2006; Walsh et al., 2006; Slupsky et al., 2007; Psihogios et al., 2008) . Characterization of this normal degree of variation in the metabolomic profiles of human biofluids is a necessary and important step in the development of metabolomics as both a research and diagnostic tool.
The effect of the oestrus cycle on rat urine metabolomic profiles has been studied (Bollard et al., 2001 ) using 1 H NMR based metabolomic analysis. Changes in the metabolomic profile of urine that correlated with different stages of the oestrus cycle were reported. The main metabolites responsible for the separation of the different phases of the oestrus cycle were citrate, 2-oxoglutarate, taurine, creatine, hippurate and succinate. Although a clear link exists between the metabolomic profile and stages of the oestrus cycle in rats, there has been no data to date investigating this relationship in humans. However, despite the lack of direct evidence, it has been proposed that gender-related differences in the elimination of citrate may be linked to estrogen levels (Zuppi et al., 1997) .
The effect of the menstrual cycle on levels of lipids and lipoproteins in the blood has been extensively studied with varying results (Walsh et al., 1994; Brinton, 1996; Muesing et al., 1996; Reed et al., 2000; Barnett et al., 2004) . A recent study compared the plasma lipid and lipoprotein levels between the follicular and luteal phases of the menstrual cycle and reported a reduction in low-density lipoprotein cholesterol (LDL-C) levels, an increase in high-density lipoprotein cholesterol (HDL-C) and a reduction in the total cholesterol (TC)/ HDL-C and LDL-C/HDL-C ratios during the luteal phase of the cycle (Barnett et al., 2004) and these findings have also been corroborated in other studies (Muesing et al., 1996; Reed et al., 2000) . In addition to the effects of the menstrual cycle on lipids and lipoproteins, studies have found that serum levels of the antioxidants co-enzyme Q 10 and a-tocopherol are significantly increased in the luteal phase while other antioxidants (g-tocopherol, b-Carotene, a-Carotene, lycopene) are not significantly changed (Lanza et al., 1998; Palan et al., 2006) . Plasma amino acid levels also fluctuate during the menstrual cycle (Lariviere et al., 1994; Moller et al., 1996; Kriengsinyos et al., 2004 ) with a decrease of many amino acids in the luteal phase.
Although the above studies highlight the importance of the relationship between menstrual cycle phase and metabolite levels, it is important to expand this to examine effects on global metabolomic profiles in numerous biofluids. Overall, this will be an important step in the development of metabolomics as a tool in nutritional and reproductive research. With this in mind, the present study investigated the influence of the different phases of the menstrual cycle on 1 H NMR derived metabolomic profiles of urine and plasma in healthy women.
Materials and Methods

Study subjects and design
Ethical approval for this project was obtained from the Research Ethics Committee, University College Dublin (UCD) and volunteers provided written consent forms. A group of 34 healthy, premenopausal women were recruited at UCD, Dublin. Prior to sample collection, volunteers attended a screening session that involved weight, height and haemoglobin measurements. Exclusion criteria were a body mass index (BMI) (in kg/m 2 ) ,18 or .30, iron deficiency anemia (haemoglobin ,11.5 g/dl), diagnosis with a medical condition and use of prescribed medication or hormonal contraceptive methods.
Subjects were instructed to keep a menstrual calendar for 1 month prior to sample collection in order to estimate the length of their cycle. Using the menstrual calendar (Table I) , urine and blood samples were collected from each woman at four different time points in one menstrual cycle. The four time points were estimated to represent four stages of the menstrual cycle (menstrual, follicular, luteal and premenstrual stages). Participants were instructed to use a luteinizing hormone (LH) urine dip strip test kit (Medimpex Ltd Inc) at home in order to determine the date of ovulation. Following serum hormonal analysis, classification of the phases was refined to define five stages of the menstrual cycle (menstrual, follicular, periovulatory, luteal and premenstrual).
Biofluid collection
Prior to blood and urine collection, subjects were instructed to fast for 12 h, limit tea and coffee consumption and abstain from fish, alcohol and vigorous exercise for 24 h.
On the morning of collection, volunteers collected their first void urine at home in a chilled graduated container and then immediately delivered it to the laboratory on ice. During the laboratory visit, a plasma sample was collected in a 4 ml lithium heparin tube and a serum sample was collected in a 6 ml vacutainer tube (BD Diagnostics). Urine and plasma samples were immediately centrifuged whereas serum samples were allowed to clot at room temperature for 30 min. All samples were centrifuged at 1800g for 10 min at 48C. Aliquots (500 ml) of the urine and plasma samples were stored at 2808C until analysis by 1 H NMR spectroscopy.
Aliquots (500 ml) of serum samples were stored at 2808C and solely used for hormonal analysis as is routine for analysis of estradiol, progesterone, LH and follicle stimulating hormone (FSH).
Measurement of serum hormone concentration
Serum estradiol (E2), progesterone, LH and FSH were measured at the Biochemistry Department, National Maternity Hospital, Dublin. The hormone levels were determined using the Roche Diagnostics Elecsys(R) 2010 Immunoassay System.
NMR spectroscopy
Urine samples were prepared by the addition of 300 ml phosphate buffer (0.2 M KH 2 PO 4 , 0.8 M K 2 HPO 4 ) to 500 ml urine. Following centrifugation at 7155g for 5 min, 10 ml TSP and 50 ml D 2 O were added to 500 ml of the supernatant. Spectra were acquired on a 500 MHz DRX NMR spectrometer (Bruker Biospin, Karlsruhe, Germany) using a Noesypresat pulse sequence at 258C. Spectra were acquired with 32 K data points and 128 scans over a spectral width of 8 kHz. Water suppression was achieved during the relaxation delay (2.5 s) and the mixing time (100 ms). All 1 H NMR urine spectra were referenced to TSP at 0.0 ppm and processed manually with XWIN NMR (version 3.5) using a line broadening of 0.2 Hz. All spectra were baseline corrected. The spectra were integrated into bins consisting of spectral regions of 0.02 ppm, using AMIX version 3.6.7 (Bruker Biospin, Karlsruhe, Germany). The water region (4.5-5.5 ppm) was excluded and the data was normalized to the sum of the spectral integral.
Plasma samples were prepared by the addition of 350 ml D 2 O and 10 ml TSP to 200 ml plasma. Spectra of samples were acquired by using a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with 32 K data points and 64 scans. The top line indicates the cycle length and the days for which sample should be collected are indicated for each of the phases.
with Bruker software and were phase and baseline corrected. The spectra were integrated into bins consisting of spectral regions of 0.02 ppm using AMIX (Bruker Biospin, Karlsruhe, Germany). The water region (4.5-5.5 ppm) was excluded and the data was normalized to the sum of the spectral integral.
Statistical analysis
The plasma and urine samples were classified into one of five menstrual phases based on the menstrual calendar and their corresponding serum hormone levels. The five phases were defined as menstrual, follicular, periovulatory, luteal and premenstrual. ANOVA was used to compare the mean concentration of the hormones estradiol, progesterone, LH and FSH across the five classified phases. Following this, the Newman -Keuls multiple comparison test was used to compare the concentrations of the measured hormones across pairs of phases. Statistical significance was assumed for P , 0.05. Analysis was carried out using GraphPad Prism 4. The NMR data were imported to SIMCA-Pþ (version 11, Umetrics, Umea, Sweden), mean centred and Pareto scaled (1/ p SD). Principal component analysis (PCA) was applied to the urine and plasma total dataset and the score plots were visually inspected for clustering trends and outliers.
Partial least squares discriminant analysis (PLS-DA) was applied to the datasets using menstrual phase as a classifier. Differences between phases as determined by PLS-DA were cross-validated by using a training set constructed from 66.6% of the samples. This training set was used to determine class membership of the remaining 33.3% of the data and this step was repeated until all samples had been left out and class membership predicted. The quality of the models formed by PCA and PLS-DA were investigated by interrogation of the R 2 and Q 2 . The R 2 parameter is a representation of how much of the variation within the dataset is explained by the components of the model. The Q 2 parameter gives an indication of how good the model is at class prediction. Validation analysis of the discriminating bin regions was performed in SPSS using ANOVA with Tukey post hoc test.
Results
For this study, 34 healthy females between the ages of 19 and 39 were recruited. Full completion of the study required participants to give blood and urine samples on four separate dates within one menstrual cycle. Of the 34 participants, 26 participants fully completed the study, six participants gave samples on three separate dates, one participant gave samples on two separate dates and one participant gave samples on one date. One volunteer was excluded due to abnormally low concentrations of estradiol (average of 158.1 + 77.6 pmol/l) and progesterone (average of 2.19 + 0.73 nmol/l) in all four samples collected. Participants had cycle lengths between 25 and 36 days and their demographic and menstrual cycle characteristics are summarized in Table II . The plasma and urine samples were classified into one of five menstrual phases based on menstrual calendar data and serum hormone levels. Thirty two samples defined as menstrual phase; these were collected during menstruation and had an average collection date of 3.8 + 1.2 days after the start of menses. Thirty samples were classified as follicular phase and the average collection day was 11.3 + 1.6 days after the start of menses. The average serum concentration of estradiol significantly increased from 124.8 + 59.4 pmol/l in the menstrual phase to 324.6 + 175.1 pmol/l in the follicular phase (P , 0.05). The 14 samples classified as periovulatory phase had significantly elevated serum concentrations of LH (P , 0.001) compared with all other phases. The average serum LH concentration of periovulatory samples was 30.6 + 18.6 IU/l compared with an average of 8.2 + 2.8 IU/l in the follicular phase and 6.5 + 3.4 IU/l in the luteal phase. Serum concentrations of FSH were also significantly elevated in the periovulatory phase compared with other phases (P , 0.001) and the serum estradiol concentration peaked in this phase with an average of 1026.5 + 527.9 pmol/l. Twenty seven samples were classified as luteal phase and these samples had significantly elevated serum progesterone concentrations compared with other phases (P , 0.001). The average serum progesterone concentration of luteal phase samples was 47.49 + 21.06 nmol/l compared with an average of 6.41 + 8.13 nmol/l in the periovulatory phase and 10.32 + 4.48 nmol/l in the premenstrual phase. Premenstrual phase samples had significantly decreased serum concentrations of progesterone and estradiol compared with levels in the luteal phase (P , 0.001). The 10 samples classified into the premenstrual phase were collected on average 26.6 + 1.7 days after the start of menses. Figure 1 displays the average serum concentration of the hormones estradiol, progesterone, LH and FSH during each phase of the menstrual cycle. Following hormonal analysis, six occurrences were found where two samples were collected within one menstrual phase for a volunteer. Due to this, six samples were removed prior to analysis of metabolic profiles leaving one sample per phase per volunteer.
The effects of the menstrual cycle on urinary metabolomic profiles PCA of 1 H NMR urine spectra resulted in a two component model with an R 2 of 0.27 and a Q 2 of 0.15. Inspection of the DModX plot revealed one outlying sample. Subsequent investigation into collection records found that the volunteer had taken an analgesic on the day prior to collection of this urine sample and thus this sample was removed. Another extreme outlying sample was also removed and the remaining spectra formed the final data set. Figure 2 displays PCA and visual inspection of these plots found no separation based on phase and no PLS-DA models were built. There were three samples outside the hotellings 95% confidence limit and removal of these outliers did not impact on the findings.
The effects of the menstrual cycle on plasma metabolomic profiles PCA of the 1 H NMR plasma spectra resulted in a three component model with an R 2 of 0.69 and a Q 2 of 0.61. The effects of the menstrual cycle on plasma were investigated by pair wise comparisons of samples according to menstrual cycle phase using PCA and PLS-DA. This analysis revealed a difference between the metabolite composition of plasma taken during the menstrual phase and the luteal phase of the menstrual cycle. PLS-DA analysis of these two groups resulted in a three component model with an R2X of 0.61 and a Q 2 of 0.41 (Fig. 3) . Cross-validation of the model, as previously described, revealed a predictability of 74 + 9%. Analysis of the corresponding loadings and VIP plots revealed a decrease in levels of alanine, glutamine, lysine, glycine, serine and creatinine and an increase in levels of hydroxybutyrate, VLDL CH 2 and acetoacetate during the luteal phase. Univariate statistical analysis of the bin regions confirmed that all metabolites with the exception of hydroxybutyrate were significantly different between the menstrual and luteal phases (Table III) . In addition, the levels of glutamine were validated using an amino acid analyser with luteal values being significantly lower than menstrual values (P , 0.0001; Fig. 4 ).
Discussion
This study is the first to delineate the relationship between the menstrual cycle and global metabolite levels in healthy women's urine and plasma using 1 H NMR based metabolomic profiling. This is important as menstrual cycle differences in metabolite composition would require consideration in future metabolomic studies. The results indicated that the menstrual cycle had no significant impact on the metabolomic profile of urine but did significantly affect that of plasma. Specifically, plasma samples taken during the luteal phase of the cycle had elevated levels of VLDL, hydroxybutyrate and acetoacetate and reduced levels of lysine, alanine, glutamine, glycine, serine and creatinine compared with plasma samples taken during the menstrual phase of the cycle. These results and those of other studies (Solomon et al., 1982; Webb, 1986; Lariviere et al., 1994; Muesing et al., 1996; Barnett et al., 2004; Kriengsinyos et al., 2004) show that the menstrual cycle The superscripts 1, 2, 3, 4, 5 refer to the phase which differs significantly. The numbering of the phases is described as follows: 1, menstrual; 2, follicular; 3, periovulatory; 4, luteal; 5, premenstrual. has a measurable impact on metabolism in healthy women. However, we found that these effects were not evident in urine leading to the conclusion that the fluctuations in ovarian hormones that are characteristic of the menstrual cycle have an impact on plasma 1 H NMR metabolite composition only and do not influence the 1 H NMR derived metabolite composition of urine.
In the present study, levels of plasma VLDL are elevated in the luteal phase of the cycle compared with the menstrual phase. This may reflect the increased demand for cholesterol by the corpus luteum during this phase of the cycle for the production of estrogen and progesterone (reviewed in Christenson and Devoto, 2003) . Results from other studies investigating changes in plasma VLDL over the menstrual cycle are varied (Ahumada Hemer et al., 1985; Woods et al., 1987; Azogui et al., 1992; Lanza et al., 1998; Barnett et al., 2004; Magkos et al., 2006) . The only study to compare VLDL levels in the very early follicular or menstrual phase found the VLDL cholesterol plasma concentration to be significantly increased in the early luteal and mid-luteal phase (Days 20-24) compared with the early follicular phase (Days 1-7; Ahumada Hemer et al., 1985) . In addition, it was reported that VLDL triglyceride plasma concentration reached the maximum value in the ovulatory phase (Woods et al., 1987) . However, other studies have found the menstrual cycle to have no significant impact on VLDL cholesterol or triglyceride concentration in plasma (Azogui et al., 1992; Barnett et al., 2004; Magkos et al., 2006) . Discrepancy between results is likely to have occurred due to differences in study design. A wide range of days have been used to classify follicular and luteal collection dates and many studies have collected samples at just two or three points in the menstrual cycle thus potentially missing the full range of hormonal fluctuations occurring during the cycle and the differences in plasma composition that may occur between these specific phases. Low participant numbers in some studies may also contribute to the inconsistent findings.
In addition to the changes found in the plasma level of VLDL, acetoacetate and hydroxybutyrate were also elevated in the luteal phase of the cycle compared with the menstrual phase. The increase in ketone body concentration in fasting luteal samples may reflect an increase in energy demand. Moreover, there is a large body of evidence that shows an increased basal metabolic rate and energy expenditure during the luteal phase (Solomon et al., 1982; Webb, 1986; Bisdee et al., 1989) .
The amino acids lysine, alanine, glutamine, glycine and serine were decreased in the luteal phase of the cycle compared with the menstrual phase. This finding is in agreement with other studies on fluctuations of amino acid levels during the menstrual cycle, where an increase in phenylalanine oxidation (Kriengsinyos et al., 2004) , leucine flux and oxidation (Lariviere et al., 1994) , decreased plasma concentrations of lysine (Kriengsinyos et al., 2004) and total plasma amino acids (Moller et al., 1996; Kriengsinyos et al., 2004) have been found during the luteal phase of the cycle. Taking the present findings together with the previous reported results, it is possible to suggest that the decreased plasma amino acid levels are reflective of Figure 4 The average plasma concentration of glutamine in menstrual and luteal phases of the menstrual cycle. Values are averages + SD. *** P , 0.0001. increased utilization. It has been proposed that changes in amino acid metabolism in the luteal phase of the cycle are due to the raised levels of progesterone and estradiol Lugibihl, 1961, 1967; Moller et al., 1996; Kriengsinyos et al., 2004) . Ovarian suppression by GnRHa administration in healthy premenopausal women causes a decrease in rates of protein metabolism (Toth et al., 2006) and a positive correlation has been found between increased phenylalaine oxidation and serum concentrations of 17b-estradiol and progesterone (Kriengsinyos et al., 2004) . Injection of progesterone into healthy men Lugibihl, 1961, 1967) results in reduced plasma amino acid levels, which was attributed to increased utilization of the amino acids by the liver. Overall, the change in energy metabolism that occurs during the luteal phase of the menstrual cycle, as depicted in Fig. 5 , may reflect the increased physiological demands of this phase of the cycle on metabolic intermediates for steroid synthesis by the corpus luteum as well as glycogenesis (Demers et al., 1977; Shapiro et al., 1980) , protein synthesis and secretion by the endometrium (Savouret et al., 1990) .
In conclusion, the primary outcome of this study is the demonstration that the menstrual cycle has a measurable influence on plasma 1 H NMR metabolite composition. This establishes a need to control for these metabolic changes in the design of future metabolomic studies involving premenopausal women and this is of particular relevance for studies where multiple timepoints are collected. Considering the results presented in this article, samples should be classified at a minimum into menstrual/early follicular and luteal phases and multiple collections should be carried out in the same phase of the menstrual cycle.
